This website is intended for US Healthcare Professionals.
This website is intended for US Healthcare Professionals.
Request a RepINDICATIONS
REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Request
a Rep 
SUPPORT AND RESOURCES: HCP AND PATIENT RESOURCES
REBLOZYL resources
Using sEPO ≤200 as a parameter in the LR-MDS treatment algorithm
George Yaghmour, MD
USC Norris Comprehensive Cancer Center & Hospital
Los Angeles, CA
Clinical response and duration in the RS- subgroups
Jamie Koprivnikar, MD
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, NJ
REBLOZYL First-line Clinical Data
View this summary of data regarding REBLOZYL as a first-line treatment for MDS-
MDS First-line Dosing Guide
Clear and detailed guidance on dosing REBLOZYL to optimize response in first-line patients with
MDS First-line Dosing and Reconstitution Guide
How to dose and administer REBLOZYL for your first-line patients with
Beta-thalassemia Dosing Flashcard
Clear and detailed guidance on dosing REBLOZYL to optimize response in patients with
REBLOZYL MDS Patient Brochure
A guide for patients living with MDS-RS–associated anemia to learn more about REBLOZYL.
MDS Education Brochure
Give this brochure to your patients and caregivers so they can learn more about MDS, MDS-associated anemia, and support for people living with MDS.
Download Brochure
MDS Patient Website
An information-filled resource where MDS patients can sign up for information about REBLOZYL.
Visit Patient Site
REBLOZYL Treatment Tracker
A tool to help you track your transfusions and communicate your symptoms to your healthcare team.
Download Tracker
REBLOZYL Beta-thalassemia Patient Brochure
A guide for patients living with beta-thalassemia–associated anemia to learn more about REBLOZYL.
Download Brochure
Beta-thalassemia Patient Website
An information-filled resource where beta-thalassemia patients with beta-thalassemia can sign up for information about REBLOZYL.
Visit Patient SiteThese EMR system resources can be used to identify patients along the REBLOZYL treatment journey. They provide instructions for creating lists or alerts to identify MDS patients who might be good candidates for REBLOZYL or patients who are currently on REBLOZYL who may require a dose adjustment. Instructions below are for the following EMR systems: Epic, Cerner, OncEMR, iKnowMed, Agnostic, and AllScripts.
Epic
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
Cerner
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
OncEMR
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
iKnowMed
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
Agnostic
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
AllScripts
ESA=erythropoiesis-stimulating agent; LR-MDS=lower-risk myelodysplastic syndromes; MDS=myelodysplastic syndromes; RS=ring sideroblast; sEPO=serum erythropoietin.
Explore REBLOZYL efficacy data in:
SUPPORT AND RESOURCES: HCP AND PATIENT RESOURCES
REBLOZYL resources
Using sEPO ≤200 as a parameter in the LR-MDS treatment algorithm
George Yaghmour, MD
USC Norris Comprehensive Cancer Center & Hospital
Los Angeles, CA
Clinical response and duration in the RS- subgroups
Jamie Koprivnikar, MD
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, NJ
REBLOZYL First-line Clinical Data
View this summary of data regarding REBLOZYL as a first-line treatment for MDS-
MDS First-line Dosing Guide
Clear and detailed guidance on dosing REBLOZYL to optimize response in first-line patients with
MDS First-line Dosing and Reconstitution Guide
How to dose and administer REBLOZYL for your first-line patients with
Beta-thalassemia Dosing Flashcard
Clear and detailed guidance on dosing REBLOZYL to optimize response in patients with
REBLOZYL MDS Patient Brochure
A guide for patients living with MDS-RS–associated anemia to learn more about REBLOZYL.
MDS Education Brochure
Give this brochure to your patients and caregivers so they can learn more about MDS, MDS-associated anemia, and support for people living with MDS.
Download Brochure
MDS Patient Website
An information-filled resource where MDS patients can sign up for information about REBLOZYL.
Visit Patient Site
REBLOZYL Treatment Tracker
A tool to help you track your transfusions and communicate your symptoms to your healthcare team.
Download Tracker
REBLOZYL Beta-thalassemia Patient Brochure
A guide for patients living with beta-thalassemia–associated anemia to learn more about REBLOZYL.
Download Brochure
Beta-thalassemia Patient Website
An information-filled resource where beta-thalassemia patients with beta-thalassemia can sign up for information about REBLOZYL.
Visit Patient SiteThese EMR system resources can be used to identify patients along the REBLOZYL treatment journey. They provide instructions for creating lists or alerts to identify MDS patients who might be good candidates for REBLOZYL or patients who are currently on REBLOZYL who may require a dose adjustment. Instructions below are for the following EMR systems: Epic, Cerner, OncEMR, iKnowMed, Agnostic, and AllScripts.
Epic
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
Cerner
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
OncEMR
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
iKnowMed
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
Agnostic
Patient Identification Resources
Instructions for creating a list of patients who may be a good fit for REBLOZYL.
Instructions for creating an alert to identify patients who may be a good fit for REBLOZYL.
Dosing Resources
Instructions for creating a list of REBLOZYL patients who may be appropriate for a dose adjustment.
Instructions for creating an alert to identify REBLOZYL patients who may be appropriate for a dose adjustment.
AllScripts
ESA=erythropoiesis-stimulating agent; LR-MDS=lower-risk myelodysplastic syndromes; MDS=myelodysplastic syndromes; RS=ring sideroblast; sEPO=serum erythropoietin.
Explore REBLOZYL efficacy data in: